Pharmacogenomics of hydroxyurea therapy and fetal hemoglobin levels in sickle cell anemia

Pharmacogenomics. 2022 May;23(7):393-396. doi: 10.2217/pgs-2022-0050. Epub 2022 May 12.

Authors

Rahyssa Rodrigues Sales¹, Bárbara Lisboa Nogueira¹, Marcelo Rizzatti Luizon^{1

2}

Affiliations

¹ Graduate Program in Genetics, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, 31270-901, Brazil.
² Department of Genetics, Ecology & Evolution, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, 31270-901, Brazil.

PMID: 35546339
DOI: 10.2217/pgs-2022-0050

No abstract available

Keywords: hydroxyurea; pharmacogenetics; pharmacogenomics; sickle cell anemia.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Anemia, Sickle Cell* / drug therapy
Anemia, Sickle Cell* / genetics
Antisickling Agents / therapeutic use
Fetal Hemoglobin / genetics
Humans
Hydroxyurea* / therapeutic use
Pharmacogenetics

Substances

Antisickling Agents
Fetal Hemoglobin
Hydroxyurea